Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 164,018Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1 Imusera

02 10Gilenya

03 3Imusera

04 1Royalty From Gilenya

05 7Royalty from Gilenya

PharmaCompass

01

Brand Name : Royalty from Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Royalty from Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 40

2019 Revenue in Millions : 88

Growth (%) : -55

blank

02

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
Antibody Engineering
Not Confirmed

03

Brand Name : Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 3,003

2019 Revenue in Millions : 3,223

Growth (%) : -7

blank

04

Brand Name : Royalty from Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Royalty from Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 35

2020 Revenue in Millions : 39

Growth (%) : -2

blank

05

Brand Name : Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 2,787

2020 Revenue in Millions : 3,003

Growth (%) : -7

blank

06

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
Antibody Engineering
Not Confirmed

07

Brand Name : Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 2,013

2021 Revenue in Millions : 2,787

Growth (%) : -28

blank

08

Brand Name : Royalty from Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Royalty from Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 971

2021 Revenue in Millions : 30

Growth (%) : 3,097

blank

09

Brand Name : Imusera

Fingolimod Hydrochloride

arrow
Antibody Engineering
Not Confirmed

10

Brand Name : Gilenya

Fingolimod

arrow
Antibody Engineering
Not Confirmed

Brand Name : Gilenya

arrow
Antibody Engineering
Not Confirmed

Fingolimod

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 925

2022 Revenue in Millions : 2,013

Growth (%) : -54

blank